Samples

Revenue segments as reported by the company.

Test revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Change in fair value of contingent consideration

Asset impairment

Restructuring

Gain on sale of RUO kit assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Invitae

Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Invitae reports strong Q4 earnings, eyes growth amid challenges

Invitae's Q4 2022 performance showcased revenue growth, improved margins, and reduced cash burn, positioning the company for sustainable growth.
Strategic investments in key growth areas and a focus on customer experience and profitability underpin Invitae's vision for the future.
Addressing supply chain challenges while seizing opportunities for expansion and innovation will be critical for Invitae's continued success.

Invitae (NVTA) reports robust Q1 earnings and advances in PCM technology

Invitae's Q1 2023 earnings call highlighted strong financial performance, operational strengths, and strategic advancements in PCM technology.
The company's focus on growth, margin expansion, and debt management underscores a path towards sustainable profitability.
While facing challenges in reimbursement dynamics and competitive landscape, Invitae remains poised to capitalize on growth opportunities.

Invitae reports Q2 revenue growth, adjusts guidance amid challenges

Invitae shows progress towards profitability with improved margins and reduced cash burn.
Challenges in hereditary cancer revenue and PGX exit impact revenue guidance.
Focus on expanding customer base, improving reimbursement, and reducing cash burn.
Continuous investment in products for future growth and competitiveness.

Invitae reports robust Q3 earnings, addresses financial concerns proactively

Invitae's Q3 2023 performance was strong, with revenue growth and margin expansion. The company faces challenges in capital structure and insurance payments but is actively addressing them. Opportunities lie in revenue growth, operational improvements, and expanding genetic testing services.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people.  Specializing in genetic diagnostics for hereditary disorders, Invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today.  What’s our plan? It takes three steps:  --Make genetic testing more affordable and accessible than ever before. --Build a secure and trusted genome management infrastructure. --Design a new global community for sharing genetic information to advance science and medicine.  Today, we are reinventing genetic testing by lowering the barriers for clinicians and patients to obtain diagnostic genetic information. Together we can improve healthcare for billions of people.

Shares of Invitae (NYSE:NVTA) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 21.25% over the past year to ($0.63), which missed the estimate of ($0.59).

Recap: Invitae Q1 Earnings

SAN FRANCISCO, May 4, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the first quarter ended March 31, 2021 signaling continued momentum into 2021. "We had a very strong start to the year, experiencing record daily volumes, and we expect that momentum to continue into the coming years," said Sean George, co-founder and chief executive officer of Invitae.

Invitae Reports $103.6 Million in Revenue Driven by 259,000 in Billable Volume in First Quarter of 2021

Invitae's supposed market leadership in genetic testing is not reflected in its declining revenue growth trend and gross margin.

Invitae: Beware Of The Hype

Activision Blizzard

Devon Energy

Lyft

Skillz

More than 1,500 publicly traded companies are scheduled to report March quarter earnings this week, with heavy representation from energy exploration and production companies.

Earnings Previews: Activision Blizzard, Devon Energy, Invitae, Lyft, Skillz

Invitae's (NVTA) first-quarter results are likely to reflect strength in genetic testing.

Invitae (NVTA) to Report Q1 Earnings: What's in the Offing?

Invitae (NVTA) closed at $36.66 in the latest trading session, marking a -1.5% move from the prior day.

Invitae (NVTA) Dips More Than Broader Markets: What You Should Know

Invitae Corporation (NVTA) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Moving Average Crossover Alert: Invitae Corp (NVTA)

Invitae (NVTA) closed at $35.96 in the latest trading session, marking a -0.39% move from the prior day.

Invitae (NVTA) Stock Moves -0.39%: What You Should Know

SAN FRANCISCO, April 20, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced its plans to open a new laboratory and production facility in North Carolina to further expand its capacity to meet the growing demand for genetic testing services globally. "As we continue to expand to support our rapid growth worldwide, we were eager to identify a location on the East Coast that would improve our ability to serve our customers, improve our operational leverage, and build a talented team with connections to a vibrant life sciences community.

Invitae to Open New Facility in North Carolina to Support Continued Growth

SAN FRANCISCO, April 20, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its first quarter 2021 financial results on Tuesday, May 4, 2021 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m.

Invitae to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021

WASHINGTON, April 19, 2021 /PRNewswire/ -- The Access to Comprehensive Genomic Profiling Coalition (ACGP) announced today the addition of AstraZeneca, Loxo Oncology at Lilly, and Invitae Corporation (NYSE: NVTA) to its coalition of companies advocating for appropriate coverage of comprehensive genomic profiling (CGP) for patients living with advanced cancer by U.S. health insurers.  "The addition of AstraZeneca, Loxo Oncology at Lilly, and Invitae to ACGP expands our growing broad-based stakeholder coalition and affirms our shared commitment to advocate for access to comprehensive genomic profiling for patients living with advanced cancer," said Jim Almas, MD, vice president and national medical director of clinical effectiveness at Labcorp, and the chairman of ACGP.

AstraZeneca, Loxo Oncology at Lilly, and Invitae Corporation Join the Access to Comprehensive Genomic Profiling Coalition

SAN FRANCISCO, April 15, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced research showing one in six people with colorectal cancer harbor genetic changes that are known to substantially increase the risk for cancer, especially in patients who were younger when diagnosed. The findings are the latest from a landmark study of genetic testing across many solid tumor cancers and were presented at the 2021 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting.

Study finds risk-causing genetic changes in nearly 1 in 6 patients with colorectal cancer

Amarin Corporation Plc

Nano-X Imaging

All three companies have enjoyed major growth catalysts since the start of 2021.

3 Top Healthcare Stocks to Buy in April

The shares of Invitae (NYSE: NVTA) have received a price target of $48 by Oppenheimer. These are the details.

Invitae Stock Price: $48 Target By Oppenheimer

SAN FRANCISCO, April 8, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, has joined eMERGE Network, a nationwide effort organized and funded by the National Human Genome Research Institute (NHGRI) that connects genetic data and electronic medical record (EMR) systems to advance the use of genetics in healthcare. As a new clinical affiliate, Invitae will provide genetic testing for a study of up to 25,000 patients to evaluate the impact of population screening.

Invitae joins NIH-sponsored study aimed at improving understanding of the links between genes and cancer, heart disease and other conditions

SoftBank Group Corp

In an announcement on Monday, Invitae Corp (NYSE: NVTA) said it will receive £830 million investment from several investors, including the Japanese multinational conglomerate holding company, SoftBank Group Corp (TYO: 9984). As per the genetic diagnostics company, it will use the investment for its growth initiatives.

Invitae to receive £830 million from SoftBank-led group of investors

Invitae stock surged as much as 7% on Monday after a report out of the Wall Street Journal said Softbank plans to lead a $1.2 billion investment in the San Francisco-based genetic testing company. The investment will come in the form of convertible debt and allow Invitae to expand its current genetic testing operations, per WSJ.

Invitae surges after report says Softbank will lead a $1.2 billion investment in the genetic-testing company (NVTA)

Invitae Corp (NYSE: NVTA) has agreed to acquire Genosity Inc, a genomics company offering software and laboratory solutions to enable the development and deployment of complex sequencing-based tests. Deal consideration of approximately $200 million includes roughly $120 million in cash and roughly $80 million in Invitae common stock.

Invitae Accelerates Personalized Oncology Testing With Genosity Acquisition

The stock price of Invitae Corp (NYSE: NVTA) has increased by over 10% pre-market. This is why it happened.

Invitae Stock Price Increased Over 10% Pre-Market: Why It Happened

A group of investors including SoftBank Group Corp will invest $1.15 billion in Invitae Corp, the U.S. genetic diagnostics company said on Monday.

SoftBank leads $1.2 billion investment in diagnostics firm Invitae

SAN FRANCISCO, April 5, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that a small group of investors, led by SB Management, a subsidiary of Softbank Group Corp., will make an investment of $1.15 billion in convertible senior notes to support the Company's future growth initiatives. "Invitae's mission is to deliver genetic information to improve healthcare for billions of people at all stages of life.

Invitae Announces $1.15 Billion Investment Supporting Ongoing Growth Initiatives

SAN FRANCISCO, April 5, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Genosity Inc. ("Genosity"), a genomics company offering innovative software and laboratory solutions to enable development and deployment of complex sequencing based tests. The acquisition would bring Genosity's specialized capabilities onto the Invitae platform to accelerate the time to market and decentralization of Invitae's personalized oncology offerings, including somatic and germline offerings poised to help transform how cancer is diagnosed, treated and monitored.

Invitae to acquire Genosity to accelerate access to personalized oncology testing worldwide

Japanese technology firm SoftBank Group Corp (OTC: SFTBY) (OTC: SFTBF) is planning to infuse around $1.2 billion via convertible debt into genetic-testing provider Invitae Corp (NYSE: NVTA), the Wall Street Journal reports. The convertible debt investment will help Invitae to expand its platform utility.

Invitae Shares Are Trading Higher On SoftBank's Potential $1.2B Debt Investment: WSJ

SAN FRANCISCO, April 1, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the availability of sponsored genetic testing for patients in the U.S., Canada, Australia and Brazil who are suspected of having or are at risk for developing some of the most common adult neurodegenerative conditions, including Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and early-onset Alzheimer's disease (AD). The new program will make genetic testing available at no charge to individuals at risk for or suspected of having these difficult-to-diagnose conditions.

Invitae introduces new program to increase access to genetic testing for adult neurodegenerative conditions

Blame a broader market sell-off of growth stocks.

News for Invitae Stock (NVTA)